{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:24:37Z","timestamp":1787970277415,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"DOI":"10.7759\/cureus.115374","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:00:30Z","timestamp":1787968830000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Engraftment Following Blinatumomab and Donor-Derived Buffy Coat Infusion in a Patient With Relapsed B-cell Acute Lymphoblastic Leukemia and High-Level Donor-Specific Anti-HLA Antibodies: A Case Report"],"prefix":"10.7759","author":[{"given":"Takahiro","family":"Maeta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-249219","article-title":"The impact of anti-HLA antibodies on unrelated cord blood transplantations","volume":"116","author":"Takanashi M","year":"2010","unstructured":"Takanashi M, Atsuta Y, Fujiwara K, et al.. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010, 116:2839-46. 10.1182\/blood-2009-10-249219","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.131","article-title":"Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT","volume":"47","author":"Yoshihara S","year":"2012","unstructured":"Yoshihara S, Maruya E, Taniguchi K, et al.. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 2012, 47:508-15. 10.1038\/bmt.2011.131","journal-title":"Bone Marrow Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-024-00283-6","article-title":"Desensitization strategies for donor-specific antibodies in HLA-mismatched stem cell transplantation recipients: what we know and what we do not know","volume":"12","author":"Zhou Y","year":"2024","unstructured":"Zhou Y, Chen YL, Huang XY, Chang YJ. Desensitization strategies for donor-specific antibodies in HLA-mismatched stem cell transplantation recipients: what we know and what we do not know. Oncol Ther. 2024, 12:375-94. 10.1007\/s40487-024-00283-6","journal-title":"Oncol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.09.005","article-title":"ASTCT consensus recommendations on testing and treatment of patients with donor-specific anti-HLA antibodies","volume":"30","author":"Kongtim P","year":"2024","unstructured":"Kongtim P, Vittayawacharin P, Zou J, et al.. ASTCT consensus recommendations on testing and treatment of patients with donor-specific anti-HLA antibodies. Transplant Cell Ther. 2024, 30:1139-54. 10.1016\/j.jtct.2024.09.005","journal-title":"Transplant Cell Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.63.550","article-title":"Extensive reduction of anti-human leukocyte antigen antibodies after chemotherapy including blinatumomab for B-cell acute lymphoblastic leukemia (Article in Japanese)","volume":"63","author":"Nishida A","year":"2022","unstructured":"Nishida A, Mitsuki T, Ishiwata K, Wake A. Extensive reduction of anti-human leukocyte antigen antibodies after chemotherapy including blinatumomab for B-cell acute lymphoblastic leukemia (Article in Japanese). Rinsho Ketsueki. 2022, 63:550-4. 10.11406\/rinketsu.63.550","journal-title":"Rinsho Ketsueki"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al.. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017, 376:836-47. 10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.283","article-title":"High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG","volume":"32","author":"Sakura T","year":"2018","unstructured":"Sakura T, Hayakawa F, Sugiura I, et al.. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG. Leukemia. 2018, 32:626-32. 10.1038\/leu.2017.283","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al.. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016, 375:740-53. 10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"key":"ref9","unstructured":"List of clinical laboratory reference values (Article in Japanese). (2026). Accessed. July 28, 2026: https:\/\/www.hosp.iwate-med.ac.jp\/hospital\/chiken\/client\/standard.html."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181b9d710","article-title":"High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation","volume":"88","author":"Ciurea SO","year":"2009","unstructured":"Ciurea SO, de Lima M, Cano P, et al.. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009, 88:1019-24. 10.1097\/TP.0b013e3181b9d710","journal-title":"Transplantation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.020","article-title":"Donor-specific anti-HLA antibodies in haploidentical stem cell transplantation with post-transplantation cyclophosphamide: risk of graft failure, poor graft function, and impact on outcomes","volume":"25","author":"Bramanti S","year":"2019","unstructured":"Bramanti S, Calafiore V, Longhi E, et al.. Donor-specific anti-HLA antibodies in haploidentical stem cell transplantation with post-transplantation cyclophosphamide: risk of graft failure, poor graft function, and impact on outcomes. Biol Blood Marrow Transplant. 2019, 25:1395-406. 10.1016\/j.bbmt.2019.02.020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0928-z","article-title":"Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody","volume":"55","author":"Chang YJ","year":"2020","unstructured":"Chang YJ, Xu LP, Wang Y, et al.. Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transplant. 2020, 55:1326-36. 10.1038\/s41409-020-0928-z","journal-title":"Bone Marrow Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.10.018","article-title":"Bortezomib and immune globulin have limited effects on donor-specific HLA antibodies in haploidentical cord blood stem cell transplantation: detrimental effect of persistent haploidentical donor-specific HLA antibodies","volume":"25","author":"Choe H","year":"2019","unstructured":"Choe H, Gergis U, Hsu J, et al.. Bortezomib and immune globulin have limited effects on donor-specific HLA antibodies in haploidentical cord blood stem cell transplantation: detrimental effect of persistent haploidentical donor-specific HLA antibodies. Biol Blood Marrow Transplant. 2019, 25:60-4. 10.1016\/j.bbmt.2018.10.018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro MJ","year":"2013","unstructured":"Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013, 15:3. 10.1186\/ar3908","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14","author":"Mei HE","year":"2012","unstructured":"Mei HE, Schmidt S, D\u00f6rner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012, 14:1. 10.1186\/ar3909","journal-title":"Arthritis Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi S","year":"2011","unstructured":"Raponi S, De Propris MS, Intoppa S, et al.. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011, 52:1098-107. 10.3109\/10428194.2011.559668","journal-title":"Leuk Lymphoma"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp MS","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, et al.. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015, 16:57-66. 10.1016\/S1470-2045(14)71170-2","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217713363","article-title":"A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia","volume":"24","author":"DasGupta RK","year":"2018","unstructured":"DasGupta RK, Marini BL, Rudoni J, Perissinotti AJ. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract. 2018, 24:453-67. 10.1177\/1078155217713363","journal-title":"J Oncol Pharm Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: Final results from a phase I study","volume":"34","author":"Goebeler ME","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, et al.. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: Final results from a phase I study. J Clin Oncol. 2016, 34:1104-11. 10.1200\/JCO.2014.59.1586","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521124-successful-engraftment-following-blinatumomab-and-donor-derived-buffy-coat-infusion-in-a-patient-with-relapsed-b-cell-acute-lymphoblastic-leukemia-and-high-level-donor-specific-anti-hla-antibodies-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:00:32Z","timestamp":1787968832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521124-successful-engraftment-following-blinatumomab-and-donor-derived-buffy-coat-infusion-in-a-patient-with-relapsed-b-cell-acute-lymphoblastic-leukemia-and-high-level-donor-specific-anti-hla-antibodies-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.115374","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}